Margarida Espadinha, former PhD student of our group, was awarded with public’s choice award, sponsored by Roche, presenting our latest results of the development of spiropyrazoline oxindoles as dual inhibitors of p53-MDM2/X PPIs at EFMC-YMCS 2022 in Nice, France.
Comments